Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer.

doi:10.1186/s12885-023-10576-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer.

BMC cancer - 1 Feb 2023

Jung Max, Rose Michael, Knuechel Ruth, Loeffler Chiara, Muti Hannah, Kather Jakob Nikolas, Gaisa Nadine T

Abstract excerpt

AIMS: Immune checkpoint inhibitor (ICI) therapy has become a viable treatment strategy in bladder cancer. However, treatment responses vary, and improved biomarkers are needed. Crucially, the characteristics of immune cells remain understudied especially in squamous differentiated bladder cancer (sq-BLCA). Here, we quantitatively analysed the tumour-immune phenotypes of sq-BLCA and correlated them with PD-L1...

Topics

Humans
Urinary Bladder Neoplasms
Carcinoma, Transitional Cell
B7-H1 Antigen
Ki-67 Antigen
Perforin
Carcinoma, Squamous Cell
CD8-Positive T-Lymphocytes
Phenotype
Lymphocytes, Tumor-Infiltrating
Biomarkers, Tumor
Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 36726072
DOI: 10.1186/s12885-023-10576-0
PMCID: PMC9890720

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics